Genetic tools, particularly CRISPR-Cas9, hold promise for curing cancer by editing genes associated with tumor growth and resistance. CRISPR-Cas9 can target and modify specific DNA sequences within cancer cells, potentially correcting mutations or silencing oncogenes that drive cancer progression.

Example: In a groundbreaking case, researchers used CRISPR to treat a patient with metastatic lung cancer. The patient’s T-cells were extracted, genetically edited using CRISPR to enhance their ability to recognize and attack cancer cells, and then reintroduced into the patient’s body. This personalized immunotherapy approach showed promising results in targeting and reducing cancerous tumors.

Additionally, CAR-T cell therapy, which involves genetically modifying a patient’s T-cells to express chimeric antigen receptors (CARs) that specifically target cancer cells, has shown success in treating certain types of leukemia and lymphoma. For example, the FDA-approved CAR-T therapy, Kymriah, has demonstrated high remission rates in patients with refractory or relapsed acute lymphoblastic leukemia.

These examples illustrate the potential of genetic tools to revolutionize cancer treatment by providing targeted, personalized therapies that can effectively combat the disease.